Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...

The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...

An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

This study compared the carbon footprint of SC and IV administration using pertuzumab/trastuzumab as a case example. A Life Cycle Assessment was conducted to compare the environmental impacts of IV ...